The Rheumatologist
COVID-19 News
You are here: Home / Articles / Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

• By

Reference

  1. Novartis AG. News release: Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients. 2017 Nov 30.

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »